CA2813048A1 — Composition for use in treating patients suffering from movement disorder

USPTO Abstract

The present invention is directed to treating movement disorders in patients by the use of an effective amount of one or more adenosine A2A receptor antagonists. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides the use of compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides the use of at least one adenosine A2A receptor antagonists, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor for treatment of Parkinson's disease. The present invention further provides the use of an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor and/or a MAO inhibitor without prior or subsequent administration of L-DOPA for delaying or removing on-set of L-DOPA motor complication and for prolonging effective treatment of Parkinson's disease.